Follow
YAN-RUIDE LI
Title
Cited by
Cited by
Year
Targeting monoamine oxidase A-regulated tumor-associated macrophage polarization for cancer immunotherapy
YC Wang, X Wang, J Yu, F Ma, Z Li, Y Zhou, S Zeng, X Ma, YR Li, A Neal, ...
Nature communications 12 (1), 3530, 2021
1162021
Development of allogeneic HSC-engineered iNKT cells for off-the-shelf cancer immunotherapy
YR Li, Y Zhou, YJ Kim, Y Zhu, F Ma, J Yu, YC Wang, X Chen, Z Li, S Zeng, ...
Cell Reports Medicine 2 (11), 2021
792021
Development of hematopoietic stem cell-engineered invariant natural killer T cell therapy for cancer
Y Zhu, DJ Smith, Y Zhou, YR Li, J Yu, D Lee, YC Wang, S Di Biase, ...
Cell Stem Cell 25 (4), 542-557. e9, 2019
752019
Myosins as fundamental components during tumorigenesis: diverse and indispensable
YR Li, WX Yang
Oncotarget 7 (29), 46785, 2016
672016
Exploring the dynamic interplay between cancer stem cells and the tumor microenvironment: implications for novel therapeutic strategies
YR Li, Y Fang, Z Lyu, Y Zhu, L Yang
Journal of Translational Medicine 21 (1), 686, 2023
592023
Targeting monoamine oxidase A for T cell–based cancer immunotherapy
X Wang, B Li, YJ Kim, YC Wang, Z Li, J Yu, S Zeng, X Ma, IY Choi, ...
Science immunology 6 (59), eabh2383, 2021
532021
Targeting immunosuppressive tumor-associated macrophages using innate T cells for enhanced antitumor reactivity
YR Li, J Brown, Y Yu, D Lee, K Zhou, ZS Dunn, R Hon, M Wilson, ...
Cancers 14 (11), 2749, 2022
452022
Advancing cell-based cancer immunotherapy through stem cell engineering
YR Li, ZS Dunn, Y Yu, M Li, P Wang, L Yang
Cell Stem Cell 30 (5), 592-610, 2023
432023
Mucosal-associated invariant T cells for cancer immunotherapy
YR Li, K Zhou, M Wilson, A Kramer, Y Zhu, N Dawson, L Yang
Molecular Therapy 31 (3), 631-646, 2023
422023
Upf proteins: highly conserved factors involved in nonsense mRNA mediated decay
P Gupta, YR Li
Molecular biology reports 45, 39-55, 2018
372018
Myosin superfamily: The multi-functional and irreplaceable factors in spermatogenesis and testicular tumors
YR Li, WX Yang
Gene 576 (1), 195-207, 2016
352016
Engineering stem cells for cancer immunotherapy
YR Li, Y Zhou, A Kramer, L Yang
Trends in cancer 7 (12), 1059-1073, 2021
322021
3D tumor spheroid and organoid to model tumor microenvironment for cancer immunotherapy
Y Zhu, E Kang, M Wilson, T Basso, E Chen, Y Yu, YR Li
Organoids 1 (2), 149-167, 2022
292022
HLA-A∗ 02: 01 restricted T cell receptors against the highly conserved SARS-CoV-2 polymerase cross-react with human coronaviruses
PA Nesterenko, J McLaughlin, BL Tsai, GB Sojo, D Cheng, D Zhao, Z Mao, ...
Cell Reports 37 (13), 2021
292021
A self-assembled implantable microtubular pacemaker for wireless cardiac electrotherapy
S Wang, Q Cui, P Abiri, M Roustaei, E Zhu, YR Li, K Wang, S Duarte, ...
Science Advances 9 (42), eadj0540, 2023
252023
Target tumor microenvironment by innate T cells
YR Li, M Wilson, L Yang
Frontiers in Immunology 13, 999549, 2022
252022
Development of stem cell-derived immune cells for off-the-shelf cancer immunotherapies
YR Li, ZS Dunn, Y Zhou, D Lee, L Yang
Cells 10 (12), 3497, 2021
242021
Development of off-the-shelf hematopoietic stem cell-engineered invariant natural killer T cells for COVID-19 therapeutic intervention
YR Li, ZS Dunn, G Garcia Jr, C Carmona, Y Zhou, D Lee, J Yu, J Huang, ...
Stem cell research & therapy 13 (1), 112, 2022
232022
An ex vivo 3D tumor microenvironment-mimicry culture to study TAM modulation of cancer immunotherapy
YR Li, Y Yu, A Kramer, R Hon, M Wilson, J Brown, L Yang
Cells 11 (9), 1583, 2022
192022
Generation of allogeneic CAR-NKT cells from hematopoietic stem and progenitor cells using a clinically guided culture method
YR Li, Y Zhou, J Yu, YJ Kim, M Li, D Lee, K Zhou, Y Chen, Y Zhu, ...
Nature Biotechnology, 1-16, 2024
182024
The system can't perform the operation now. Try again later.
Articles 1–20